Abstract
Cigarette smoke mediated cellular proliferation
For example, in transformed lung epithelial type-II cells cigarette smoke condensate at low concentration (0.1 g/ml) induced cancer cell proliferation, DNA synthesis, reduced glutathione levels and intercellular adhesion molecule-1 expression without any significant change in reactive oxygen species (ROS) and superoxide radicals production [8] . Another recent study has shown that critical miRNAs involved with regulating stress response, apoptosis, proliferation, angiogenesis and expression of genes were found to be down-regulated in the lungs of rats exposed to environmental cigarette smoke for 28 days [9] . Benzo [a] [10] . Moreover, exposure of human airway epithelial cells to cigarette smoke, results in an increase in EGFR activation over time, leading to prolonged signalling by the EGFR and which may therefore contribute to uncontrolled lung cell growth [11] Cigarette smoke mediated lung destruction
pyrene (B[a]P) is one of the strongest carcinogens present in both the environment and cigarette smoke. B[a]P has now been shown to increases the proliferative potential of lung adenocarcinoma cells through the epidermal growth factor receptor (EGFR) signalling pathway by overexpression of phosphorylated EGFR protein and inducing expression of the ligands for EGFR such as amphiregulin and epiregulin
One way by which cigarette smoke extract mediates cellular destruction in the lung has been shown to be via disruption of tubulin-microtubules structure and function, and it has been suggested that this results in cellular apoptosis and subsequent tissue damage in smokers [12] In addition, p21 is overexpressed in alveolar epithelial cells in response to cigarette smoke [13] , leading to cellular senescence, and if p21 is disrupted, this response is attenuated, which indicates how critical regulators designed for the protection of the host, can lead to organ damage in the presence of cigarette smoke [14] . [16] .
Vascular endothelial growth factor (VEGF) is fundamental to the development and maintenance of vasculature. Expression of critical members of this signalling pathway has been shown to be reduced in the lungs of both smokers and patients with COPD compared with non-smokers [15]. Cigarette smoke down-regulated vascular endothelial growth factor receptor (VEGFR)-2 expression, endothelial nitric oxide synthase (eNOS) levels and VEGF-induced VEGFR-2 phosphorylation in human lung microvascular endothelial cells, which results in impaired VEGF-induced endothelial cell migration and angiogenesis

In COPD, defective efferocytosis (apoptosis and alveolar macrophage phagocytic function) may lead to secondary necrosis and tissue damage. Cigarette smoke has been shown to significantly decrease alveolar macrophage phagocytic function in both COPD patients and healthy smokers compared with control subjects indicating that smoking-related reduction in alveolar macrophage (AM) phagocytic ability may play important roles in the destruction of lung [17]. These differences (i.e. proliferative versus destructive effects) may be due to either cigarette smoke targeting different cell types, or may be cell specific effects. Alternatively, these differential effects may be caused by differential regulation of critical pathways via aberrant epigenetic regulation.
Molecular genetic studies of lung cancer frequently reveal multiple genetic and epigenetic changes including DNA sequence alterations, copy number changes and aberrant promoter methylation [18, 19] . The role of epigenetics in cancer is increasingly recognized as a major focus for translational research. NSCLC is no exception and DNA CpG methylation is recognized as having both predictive and prognostic significance in NSCLC [20, 21] . The three main, inter-related forms of epigenetic regulation are: DNA methylation, genomic imprinting and histone modification, all of which have important roles in disease [22] .
DNA methylation and lung cancer
The importance of DNA methylation in the development of lung cancer was recently demonstrated when it was shown that the transformation efficiency for immortalization of normal bronchial epithelial cells could be enhanced by low dose exposure to carcinogens. The mechanism underpinning this involved hypermethylation of 5-10 genes due to elevated expression of DNA methyltransferase 1 (DNMT1). Ablation of DNMT1 was shown to reverse this process.
Moreover, stable 'knockdown' of DNMT1 prior to carcinogen exposure was sufficient to prevent cellular transformation [23] . 
Histone post-translational modifications and lung cancer
KEAP1-NRF2-ARE signalling pathway
One of the most important oxidative stress protective pathways is the Kelch-like ECH-Associated Protein 1 (KEAP1)-NFE2-Related Factor 2 (NRF2)-antioxidant response element (ARE) or KEAP1-NRF2-ARE signalling pathway (
Hypoxia-inducible factor-1␣
Hypoxia is a common event in solid tumours [95] [104] .
HIF-1␣ has recently been shown to regulate epigenetic regulators including lysine demethylases [105] [106] [107] .
Epigenetic mechanisms have been shown to affect HIF-1␣ mainly through stabilization of the protein itself, by HDACs [108] [109] [110] [111] . In addition, the MTA-1 has also been shown to both stabilize HIF-1␣ and enhance tumour metastasis via angiogenesis through direct associations with HDACs [112, 113] . Indeed, in many cell culture models inhibition of HDACs has been shown to both destabilize HIF-1␣ and reduce angiogenesis [108, [114] [115] [116] [117] [118] .
HIF-1␣ functionally associates with lysine acetyltransferases (KATs and HDACs) to regulate gene expression in response to hypoxia [111, [119] [120] [121] [122] [123] . Indeed for some target HIF-1␣ responsive genes both lysine acetyltransferases and HDACs were required for greater than 90% of the genes response, suggesting that a functional interaction between lysine acetylases and HDACs are essential for nearly all HIF-1␣ responsive transcription [123] .
PGC-1␣
Peroxisome proliferator-activated receptor-␥ co-activator 1␣ (PGC-1␣) was originally isolated from a brown fat cDNA library linked to adaptive thermogenesis [124] . Since then it has been associated with various other important pathways including mitochondrial oxidative metabolism, adipocyte cell fate decision, glucose homeostasis and hepatic gluconeogenesis [125] . It is well established that PGC-1␣ acts as a transcriptional co-activator associating with both HDACs [126] and lysine acetyltransferases [127] [128] [129] [130] [131] . PGC-1␣ can regulate the expression of uncoupling protein 2 and uncoupling protein 3, both of which are now understood to be able to mitigate ROS formation [132, 133] . Nitric oxide, a critical regulator of oxidative stress has also been shown to regulate the protection of mitochondria by modulating PGC-1␣ expression, resulting in changes to the expression of mitochondrial ROS detoxification system members [134] .
to regulate expression of genes (Table 2). Under various conditions of stress PGC-1␣ has been shown to increase the expression of major antioxidant enzymes including copper/zinc SOD (SOD1), manganese SOD (SOD2), catalase and GPx1
The One of the genes negatively regulated by glucocorticoids is SP-A which, as described, has a role in regulating NFB in airway epithelial cells [137] . [138] . It has been suggested that IKBA, a key regulator of NFB activity is a major contributor to the anti-inflammatory effects of SP-A [137] .
GR regulates the expression of the SP-A gene via chromatin remodelling and assembly of complexes containing either HDACs or KATs to functionally regulate transcription of this gene
As 
Targeting epigenetic mechanisms in COPD and NSCLC
Epigenetic targeting remains an attractive target for pharmacological intervention in disease. Two main epigenetic therapeutic avenues have been extensively explored for the treatment of NSCLC. These are aimed at targeting DNA methylation via DNMT inhibitors (DNMTi), and at targeting histone acetylation via HDAC inhibitors. As DNA methylation is a common event in lung cancer [18-21], many in vitro studies involving DNMTi have been carried out demonstrating the loss of expression of critical genes in NSCLC and showing that such genes can be reactivated in response to DNMTi treatment [173-183]. Intriguingly it has recently been shown that DNA CpG hypermethylation and downregulation of the oxidative stress sensor KEAP1 is common in NSCLC cell lines and tumour tissues, and can be reactivated following treatments with the DNMTi 5-aza-2Ј-dexoycytidine (Decitabine) [83].
We have recently extensively reviewed the potential for therapeutic targeting of HDACs in NSCLC and other disease conditions involving chronic inflammation in great detail and the reader is directed to the following reviews [184, 185] [184] . [189] . Recent work has however found that this compound also acts as a HDAC inhibitor [190] .
Theophylline -a novel agonist of HDACs
One of the most interesting recent new developments in relation to epigenetic targeting of COPD has been the discovery that theophylline an agent developed for the treatment of COPD can act as an agonist of HDACs [40]. As decreased HDAC activity has been observed in patients suffering from COPD [37], several clinical trials are in process to assess the clinical efficacy of this drug in both COPD and NSCLC (Table 3).
Current clinical trials involving epigenetic therapies in COPD and NSCLC
A large number of clinical trials in patients with COPD or NSCLC involving epigenetic therapies have been either completed or are ongoing (Table 3), and as these and other trials proceed, greater understanding of the potential side effects and dose-limiting toxicities of these drugs begins to emerge, and for the most part these first generation inhibitors have shown well-tolerated safety profiles
Dietary HDAC inhibitors as therapeutic agents to target COPD or NSCLC?
Dietary interventions with cruciferous vegetables (and in particular Broccoli) may prove to have a critical role in the treatment of COPD or in preventing the development of lung cancer.
Sulforaphane
A compound found in broccoli, L-sulforaphane (SFN) was originally identified as a potential chemopreventative compound, which could protect against oxidative stress by activating phase II antioxidant enzymes
Evidence [191] [192] [193] , causing cell cycle arrest [194] and by sensitizing cells to tumours necrosis factor-related apoptosis-inducing ligand (TRAIL) [195] [196] . [197, 198] , and has been suggested to be a dietary intervention option in the treatment of inflammatory lung disease [199] . Curcumin has received a lot of attention as an 'anticancer' agent including studies on its potential effectiveness in lung cancer [200] [201] [202] [203] , and clinical trials have shown that it is well tolerated and lacks significant toxicity [204] [205] [206] [207] [208] , and HDACs [209, 210] , although other studies have found that curcumin has no effect on HDACs [208] .
. Sulforaphane has also been shown to have efficacy in a mouse model. In this model, the A/J mouse model, following administration of tobacco carcinogens, lung adenomas appear during weeks 16 to 19 after administration, and adenocarcinomas occur generally during weeks 28 to 36. When the effects of sulforaphane on this model were tested, no effects on adenoma formation were observed but significant inhibition in the progression to adenocarcinomas was observed in the group fed sulforaphane, (1.5 mol/g diet), compared to the control
Curcumin
Another compound that has been shown to target epigenetic mechanisms may also play a role in the treatment of COPD is curcumin (diferuloylmethane). This is a compound derived from turmeric and has been shown to have potent anti-inflammatory properties and antioxidant properties
. One of the mechanisms by which curcumin appears to act in its capacity as an anti-cancerous agent involves its ability to inhibit both lysine acetyltransferases
Curcumin inhibits NFB mediated responses either by either preventing the phosphorylation of IKBA [211] , or by preventing its degradation [210] , thereby reducing nuclear translocation NFB.
It has also been suggested that curcumin may also prevent NFB mediated chromatin remodelling through its ability to inhibit lysine acetyltransferases. The inhibition of NFB in turn leads to the down-regulation of pro-inflammatory cytokines such as
Chemokine, CXC Motif, Ligand CXCL1 and CXCL2 [212] , or upregulation of genes that control pro-inflammatory genes such as mitogen-activated protein kinase phosphatase-5 [213] . [214] (Fig. 1) [219, 220] , and as such may function to affect epigenetic regulation of genes during oxidative stress. Indeed, EGCG has been shown to have efficacy in enhancing the expression of antioxidant genes in a mouse model of pulmonary fibrosis but the molecular mechanism underpinning this has yet to be determined [221] . Suggestive evidence has also emerged from a colon cancer study in mice where EGCG was found to up-regulate the expression of NRF2 [222] , and gene expression arrays on the effect of EGCG on bronchial epithelial cells has identified genes affected by this compound [223] . In addition, EGCG has been shown to attenuate cigarette smoke induced NFB activation in normal human bronchial epithelial cells [224] , and has also been shown to inhibit IKK activation and IL-8 gene expression in NSCLC cells [225] . Several studies have shown the efficacy of EGCG as a potential chemopreventative treatment for NSCLC [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] .
Curcumin and similar dietary compounds have been shown to induce HO-1 and NRF2 in breast cells
Epigallocatechin 3-gallate (EGCG)
Another dietary polyphenol, which may prove of use in the treatment of COPD or NSCLC, is the green tea polyphenol EGCG. This compound has been shown to inhibit DNMTs
Caveats to the potential usefulness of EGCG in the treatment of pulmonary disease are that it has been linked to the development of asthma [241] .
Can dietary epigenetic inhibitors work in the clinical setting?
Initial epidemiological evidence suggested a link between dietary isothiocyanate (of which sulforaphane is a member) intake and a reduced risk of developing lung cancer [242] [243] [244] [245] [246] [250] .
HDi have been shown to reactivate BRM [62] , but inhibit its function, and subsequent removal of the HDi restores functional activity [63] . As such, it may be important to design staggered therapeutic interventions with HDi to allow the critical cellular functions of reactivated genes to take effect. [251] . In a recent phase II clinical trial in patients with advanced pancreatic cancer, even though patients received up to 8 g of curcumin by mouth daily until disease progression, with restaging every 2 months, the bioavailable levels of curcumin achieved in plasma were within the range of 22 to 41 ng/ml [252] . However, curcumin bioavailability has been increased through heat treatment [253] , or by the synthesis of novel derivatives [254] , and should lead to better compounds for use in the clinical setting. In contrast the bioavailability of SFN is increased if cruciferous vegetables are eaten raw rather than heat treated [255] [256] [257] . It is clear that further efforts are required to understand the bioavailability and pharmacokinetics of these dietary derived natural compounds. For instance, in a recent study in human volunteers it was found that repeated ingestion of broccoli did not lead to higher plasma levels of SFN [258] .
Issues of bioavailability may also be encountered in relation to efficacy of dietary epigenetic interventions in the treatment of COPD and NSCLC. For instance it is well established that curcumin is not easily bioavailable
Finally, while HDi may be beneficial for the treatment of disease, they may not be of great use in targeting oxidative stress induced disease. In this regard, they have been shown to induce apoptosis in cancer cells by inducing oxidative stress [259] [260] [261] . Fig. 1 
Lung cancer and COPD are leading causes of morbidity and mortality in the United States and worldwide. They share a common environmental risk factor in cigarette smoke exposure and a genetic predisposition represented by the incidence of these diseases in only a fraction of smokers. The presence of COPD increases the risk of lung cancer up to 4.5-fold. However, in addi-
